Kalaris Therapeutics, Inc. GAAP EPS of -$0.61

Published 2 months ago Positive
Kalaris Therapeutics, Inc. GAAP EPS of -$0.61
Auto
* Kalaris Therapeutics, Inc. press release [https://seekingalpha.com/pr/20199341-kalaris-reports-second-quarter-2025-financial-results-and-provides-business-updates] (NASDAQ:KLRS [https://seekingalpha.com/symbol/KLRS]): Q2 GAAP EPS of -$0.61.

MORE ON KALARIS THERAPEUTICS, INC.

* Historical earnings data for Kalaris Therapeutics, Inc. [https://seekingalpha.com/symbol/KLRS/earnings]
* Financial information for Kalaris Therapeutics, Inc. [https://seekingalpha.com/symbol/KLRS/income-statement]

More News

Leishen Energy(LSE) Makes a Strong Debut at ADIPEC Abu Dhabi, Embarking on a New Chapter of Strategic Expansion in the Middle East and International Markets

30 minutes ago Positive

Startups from Australia, India and UAE crowned winners in L'Oréal Groupe's biggest Beauty Tech competition across South Asia Pacific, Middle East and North Africa

50 minutes ago Positive

Kirin: Development of a Fermented Ingredient Derived from Coffee Cherries to Enhance Body and Aroma Contributing to the Sustainability of Coffee Farms, Reduction of Environmental Impact, and Addressing Alcohol-related Social Issues

54 minutes ago Positive

ROSEN, HIGHLY REGARDED INVESTOR COUNSEL, Encourages Cytokinetics, Inc. Investors to Secure Counsel Before Important November 17 Deadline in Securities Class Action – CYTK

54 minutes ago Positive

FLY Investor News: If You Have Suffered Losses in Firefly Aerospace Inc. (NASDAQ: FLY), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

1 hour ago Positive